POverview
Piramal Pharma is a diversified pharmaceutical group with three divisions: Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and the Consumer Products Division (CPD). PPS operates as a contract development and manufacturing organization, providing development and manufacturing services across the drug lifecycle for clients in North America, Europe, and Asia through a globally connected network. PCC specializes in complex hospital generics, particularly inhaled anesthetics, serving markets in the USA, Europe, and over 100 countries. CPD leads consumer healthcare in India with brands such as Littles, Lacto Calamine, i-pill, Tetmosol, Polycrol, and Tri Activ, and the company serves pharmaceutical companies, hospitals, and consumers by leveraging its manufacturing scale and distribution network.
Work here?Claim your company
About Piramal Pharma
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Maharashtra, India
Founded
2020
Get referred to Piramal Pharma
See people who can refer or advise you
Simplify's take
What believers are saying
- Yapan Bio became a subsidiary on August 18, 2026, strengthening biologics and vaccines.
- Kenalog supply starts in Q2FY27, adding $30-40 million annualized revenue.
- Morpeth solar begins Q1 2027, cutting Scope 1 and 2 emissions 42% by FY2030.
What critics are saying
- FDA issued a Form 483 with seven observations at Morpeth on September 14, 2026.
- Q1 FY27 revenue fell 17.5%; inventory destocking and weak early-stage CDMO inflows persist.
- If Morpeth remediation slips, UK supply, customer trust, and CDMO wins stall into 2027.
What makes Piramal Pharma unique
- Piramal spans CDMO, hospital generics, and Indian consumer healthcare across 100+ countries.
- PPS offers ADCs, sterile fill-finish, peptides, and biologics through Yapan Bio.
- Kenalog and inhaled anesthetics give Piramal harder-to-replicate niche products and hospital channels.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Stock Options
Growth & Insights and Company News
6 month growth
12%1 year growth
12%2 year growth
18%Telecom could become one of Nifty's biggest sectors after financials, says ICICI Securities. October 29, 2026 | 01:50 IST Pankaj Pandey, Head of Retail Research at ICICI Securities, expects another 16-20% telecom tariff hike to improve 5G monetisation and cash flows, while limited competition could support long-term growth. The brokerage also highlighted Radico Khaitan's premiumisation strategy and Piramal Pharma's expanding CDMO business as key investment themes. Telecom could emerge as one of the largest sectors in the Nifty after financials as another round of tariff hikes boosts earnings and free cash flows, according to Pankaj Pandey, Head of Retail Research at ICICI Securities. The brokerage also remains positive on Radico Khaitan and Piramal Pharma, citing growth in premium liquor and contract manufacturing. Pandey said he would not comment on Jio Platforms specifically but remained constructive on the telecom sector's outlook. "After BFSI, this is going to be the single or the biggest sector in terms of weightage in Nifty going forward," Pandey said. He noted that the last telecom tariff hike took place in July 2024 and expects another round of price increases. "We are expecting a hike of nearly 16% to 20%, and that will lead to stronger monetisation of 5G capex," he said. Pandey said telecom operators are entering a phase where investments in 5G can begin generating higher returns. He pointed out that companies such as Bharti Airtel are already producing healthy free cash flows, which can be invested in new growth areas. "The free cash flows are expected to be quite better, which they can probably deploy in data centers, which is what Airtel is doing," he said. He also expects competition in the telecom industry to remain limited, with only a few strong players likely to dominate the market. "You will have two strong players, and tariff hikes are required for Vodafone to survive," Pandey said, adding that the industry's structure supports long-term earnings visibility. Radico Khaitan stands out Among the companies that reported quarterly earnings, Pandey said Radico Khaitan delivered one of the strongest performances. He believes the premium spirits business will continue to drive growth despite higher input costs. "The company has upgraded the growth to 30%. The prestige and above segment will continue to deliver with better margins," he said. Pandey noted that Radico Khaitan's earnings before interest, taxes, depreciation, and amortisation (EBITDA) margins have improved significantly from the 11-13% range seen a few years ago, supported by a richer product mix led by premium brands. Piramal Pharma's CDMO business remains a key growth driver Pandey also highlighted Piramal Pharma, saying its contract development and manufacturing organisation (CDMO) business continues to perform well. "54% of their revenue is coming from CDMO, which has grown at about 38%," he said. He added that ICICI Securities remains positive on the CDMO opportunity because of a large patent expiry cycle over the coming years. "The overall expiry of nearly $135 billion over the next four-five years... the opportunity size is a lot bigger, approaching about $300 billion," Pandey said. The brokerage continues to maintain a buy rating on both Radico Khaitan and Piramal Pharma, supported by their earnings outlook and structural growth opportunities. For the full interview, watch the accompanying video ICICI Securities' Pankaj Pandey on telecom tariff hikes and two stocks he likes Catch all the latest updates from the stock market here Catch the latest updates from the Jio Platforms Listing here Disclosure: Reliance Industries Ltd, which owns Jio, is the sole beneficiary of Independent Media Trust that controls Network18, the parent company of CNBCTV18.com. NOTE TO READERS Disclaimer: The views and tips expressed by investment experts on CNBCTV18.com are their own, not of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.
FII increases stake: Helios Flexi, Mid and Small Cap funds-held Pharma stock sees sharpest rally in 2 years; management raises FY27 revenue growth expectations. Management has raised its FY27 revenue growth expectation to 19 to 20 per cent and expects meaningfully higher profitability, supported by a healthy Order Book and a seasonally stronger second half. Key takeaways. Piramal Pharma has been working to improve utilisation across its global manufacturing network while expanding higher-value contract development and manufacturing capabilities. The company reported a sharp operating recovery in Q2FY27, with consolidated revenue from operations rising 28 per cent YoY to Rs 2,617 crore and earnings before interest, Tax, depreciation and amortisation (EBITDA) increasing 72 per cent to Rs 385 crore. EBITDA margin expanded to 14.7 per cent from 11 per cent in the corresponding quarter last year, reflecting better capacity utilisation, operating leverage and cost-control measures. Piramal Pharma reported a profit after tax of Rs 5 crore, compared with a loss of Rs 99 crore in Q2FY26. Profit before tax improved to Rs 82 crore from a loss of Rs 46 crore, although a higher tax expense of Rs 77 crore limited the conversion of operating gains into net profit. The Contract Development and Manufacturing Organisation (CDMO) business remained the main growth engine, with quarterly revenue rising 36 per cent YoY to Rs 1,424 crore. Complex Hospital Generics (CHG) revenue grew 32 per cent to Rs 849 crore, aided by inhalation anaesthesia sales in markets outside the US and the integration of Kenalog. Piramal Consumer Healthcare (PCH) revenue increased 13 per cent to Rs 359 crore, supported by power brands and e-commerce. For the first half of FY27, revenue rose 23 per cent YoY to Rs 4,887 crore, while EBITDA grew 72 per cent to Rs 669 crore. The first-half net loss narrowed to Rs 64 crore from Rs 181 crore a year earlier. Management has raised its FY27 revenue growth expectation to 19 to 20 per cent and expects meaningfully higher profitability, supported by a healthy Order Book and a seasonally stronger second half. Within CDMO, on-patent commercial revenue grew 39 per cent in the first half, while antibody-drug conjugate revenue rose 51 per cent. The company added 22 customers and increased its Phase III development pipeline to 28 molecules from 25 at March 2026. Its Lexington sterile fill-finish expansion remains on track, while the acquisition of a controlling stake in Yapan Bio is intended to strengthen biologics capabilities. As of 9:40 am on October 28, 2026, Piramal Pharma shares were trading at Rs 223.05, up 12.4 per cent from the previous close of Rs 198.45. The stock was about 1.6 per cent below its 52-week high of Rs 226.60. The company's market capitalisation stood at around Rs 26,421 crore. Foreign institutional ownership increased by 1.14 percentage points to 13.65 per cent, while domestic institutional ownership was broadly stable at 14.43 per cent. The stock is also held by three mutual fund schemes of Helios Mutual Fund. Helios Flexi Cap Fund holds 24.57 lakh shares valued at approximately Rs 50.74 crore, representing 0.58 per cent of its portfolio. Meanwhile, Helios Mid Cap Fund holds 13.01 lakh shares worth Rs 26.87 crore, accounting for 1.14 per cent of its portfolio, while Helios Small Cap Fund holds 13.29 lakh shares valued at Rs 27.44 crore, representing 1.46 per cent of its portfolio. Collectively, these three Helios mutual fund schemes hold approximately 50.86 lakh shares worth Rs 105.05 crore in the company. What this means for investors. The results strengthen the case that Piramal Pharma's recovery is becoming broader than a single-business improvement. CDMO growth and rising utilisation are particularly important because the business offers the largest scope for operating leverage as overseas assets scale. CHG has added support through ex-US inhalation anaesthesia sales and Kenalog, while PCH continues to provide steadier growth through brands, distribution and digital channels. The higher FY27 revenue outlook indicates management sees sufficient momentum entering the second half. Profitability remains the key test. The move to a quarterly profit is encouraging, but Rs 5 crore of net profit against Rs 385 crore of EBITDA shows that tax costs and below-EBITDA charges still constrain earnings conversion. The company also carried net debt of Rs 4,164 crore at March 31, 2026, making sustained cash generation and margin improvement important. At an enterprise value to trailing EBITDA multiple of 24.47 times, the valuation places importance on continued utilisation gains, CDMO order conversion and timely ramp-up of specialised capacity. Disclaimer: The article is for informational purposes only and not investment advice.
Piramal Pharma Limited announces results for Q2 and H1 FY27. PRNewswire Mumbai (Maharashtra) [India], October 28: Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30th September 2026. Key Highlights - Broad-based Revenue Growth: Revenue grew 28% YoY in Q2FY27 and 23% YoY in H1FY27, driven by strong performance across all three businesses. - Significant Profitability Improvement: EBITDA increased 72% YoY in Q2FY27 and H1FY27, with over 350bps EBITDA margin expansion in both periods. This was driven by higher capacity utilization, operating leverage, disciplined execution, and sustained cost optimization initiatives. - Robust RFP Activity and Order Inflows: Added 22 new customers and successfully hosted 110 customer audits in H1FY27. - Best-in-Class Quality & Compliance: Successfully completed 12 regulatory inspections and 110 customer audits during H1FY27, while maintaining the Company's track record of no Official Action Indicated classifications across US FDA inspections. - Upgrade FY27 Outlook: Based on the strong first-half performance and continued business momentum, Sarameltzergallery upgrade its FY27 outlook and now expect revenue growth of 19% to 20%, accompanied by meaningfully higher profitability. Nandini Piramal, Chairperson, Piramal Pharma Limited said, "Sarameltzergallery delivered a strong H1FY27, with revenue growth of 23% and EBITDA margin expansion of over 350 basis points, driven by healthy demand across its businesses, disciplined execution, and improved operating leverage. The performance was led by its CDMO business, which grew 28% on the back of strong order inflows and robust execution. Its CHG business complemented this momentum with 24% growth, supported by inhalation anesthesia sales in ex-US markets and the integration of the Kenalog, while Consumer Healthcare continued to deliver steady 14% growth through the strong performance of Power Brands and e-commerce. With H2 typically stronger than H1, Sarameltzergallery is well positioned to deliver a strong full-year performance, supported by a healthy order book, encouraging customer engagement, and continued operating discipline." 1. Exceptional items include, one time insolvency proceeds received from a claim filed against a third-party supplier of its complex hospital generics business, with the NCLT in November 2023 Earnings Conference Call Piramal Pharma Limited will be hosting a conference call for investors / analysts on 28th October 2026 from 10:00 AM to 10:45 AM (IST) to discuss its Q2 and H1 FY2027 Results. The dial-in details for the call are as under: About Piramal Pharma Limited: Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare (PCH) business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. (ADVERTORIAL DISCLAIMER: The above press release has been provided by PRNewswire. ANI will not be responsible in any way for the content of the same.) Disclaimer: No Business Standard Journalist was involved in creation of this content First Published: Oct 28 2026 | 12:05 PM IST
Piramal Pharma Q2 Results: Firm swings to profit as revenue jumps 28%, led by CDMO growth. October 28, 2026 | 11:34 IST AI Summary Piramal Pharma returned to profitability and raised its full-year guidance, driven by surging contract manufacturing pipelines and wider operating margins across global facilities. Discover how leadership plans to handle the upcoming distribution transition. Drug firm Piramal Pharma Ltd on Tuesday (October 27) reported a net profit of ₹5.58 crore for the second quarter of financial year 2026-27, compared with a loss of ₹99.2 crore in the year-ago period. Revenue rose 28% year-on-year to ₹2,617 crore from ₹2,044 crore. Earnings before interest, tax, depreciation and amortisation (EBITDA) increased to ₹348.7 crore from ₹158.7 crore a year earlier. EBITDA margin expanded to 13.3% from 7.8%, an improvement of 550 basis points. The company upgraded its financial year 2026-27 outlook, citing its first-half performance and continued business momentum. It now expects revenue growth of 19% to 20%, accompanied by meaningfully higher profitability. Revenue growth across businesses Piramal Pharma said revenue grew 28% year-on-year in Q2 FY27 and 23% in the first half of FY27, supported by growth across all three businesses. EBITDA increased 72% year-on-year in both periods, with EBITDA margin expanding by more than 350 basis points in each period. The company attributed the improvement in profitability to higher capacity utilisation, operating leverage, disciplined execution and sustained cost optimisation initiatives. During the first half, Piramal Pharma added 22 new customers and hosted 110 customer audits. It also completed 12 regulatory inspections while maintaining its track record of no Official Action Indicated classifications across US Food and Drug Administration (USFDA) inspections. CDMO business expands pipeline The Contract Development and Manufacturing Organisation (CDMO) business recorded broad-based growth across its Indian and overseas facilities, supported by commercial demand, improved execution and cost management. India and North America led performance across the network. The company's Phase III pipeline increased to 28 molecules from 25 as of March 2026. Innovation-related revenue grew 24% in H1 FY27, while revenue from on-patent commercial manufacturing rose 39%. Revenue from antibody-drug conjugate (ADC) services increased 51% year-on-year during the first half. Piramal Pharma strengthened its biologics capabilities through the acquisition of a controlling stake in Yapan Bio. Its Lexington expansion remains on track and will add sterile fill-finish capabilities, completing its integrated ADC offering. The company also commissioned a new microbiology laboratory at the site. Complex hospital generics In Complex Hospital Generics (CHG), Piramal Pharma maintained a 48% value share in the US Sevoflurane market and retained the number-one position in the US Intrathecal Baclofen market, according to IQVIA. Kenalog contributed to CHG revenue in Q2 FY27 and is expected to be an important growth driver for the business in FY27. The company continued working with suppliers to maintain product availability for injectable pain management. It also continued investing in 505(b)(2) products, complex and differentiated generics, branded products, in-licensing and co-development to strengthen its specialty portfolio. Consumer healthcare growth Piramal Consumer Healthcare's power brands grew 21% year-on-year in H1 FY27 and contributed 53% of the business's sales. E-commerce revenue increased 32% during the first half, accounting for 28% of consumer healthcare sales. The company continued focusing on launches with higher growth potential and premiumisation, including the launch of the Vizible range under Lacto Calamine. It invested approximately 11% of consumer healthcare sales in media and trade promotions across digital and traditional channels. Piramal Pharma said the distribution agreement with Bayer will expire in December 2026. The transition is being jointly managed to ensure business continuity, with no material impact expected on the company's FY27 guidance. Nandini Piramal, Chairperson, Piramal Pharma Limited said, "We delivered a strong H1FY27, with revenue growth of 23% and EBITDA margin expansion of over 350 basis points, driven by healthy demand across our businesses, disciplined execution, and improved operating leverage. The performance was led by our CDMO business, which grew 28% on the back of strong order inflows and robust execution. Our CHG business complemented this momentum with 24% growth, supported by inhalation anaesthesia sales in ex-US markets and the integration of the Kenalog, while Consumer Healthcare continued to deliver steady 14% growth through the strong performance of Power Brands and e-commerce. With H2 typically stronger than H1, we are well positioned to deliver a strong full-year performance, supported by a healthy order book, encouraging customer engagement, and continued operating discipline." Shares of Piramal Pharma Ltd ended at ₹198.45, up by ₹3.30, or 1.69%, on the BSE.
Piramal Pharma swings to ₹5 crore profit in Q2 as revenue rises 28%. The Mumbai-based pharmaceutical company recorded higher operating revenue during the quarter, while its total expenses also increased year-on-year. By PTI. Updated - October 28, 2026 at 12:49 AM. Piramal Pharma reported a consolidated net profit of ₹5 crore in the July-September quarter as revenue from operations increased year-on-year. Piramal Pharma on Thursday reported a consolidated net profit of Rs 5 crore in the July-September period of the current fiscal year. The pharma company had posted a loss of Rs 99.22 crore in the year-ago period, the company said in a regulatory filing on Tuesday evening. Revenue from operations rose to Rs 2,617.06 crore in the second quarter of the ongoing fiscal year, up from Rs 2,043.72 crore in the year-ago period, the Mumbai-based firm said. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.
Piramal Pharma is Hiring for 265 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
About Piramal Pharma
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Maharashtra, India
Founded
2020
Piramal Pharma is Hiring for 265 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs